Cargando…
Functional muscle hypertrophy by increased insulin‐like growth factor 1 does not require dysferlin
INTRODUCTION: Dysferlin loss‐of‐function mutations cause muscular dystrophy, accompanied by impaired membrane repair and muscle weakness. Growth promoting strategies including insulin‐like growth factor 1 (IGF‐1) could provide benefit but may cause strength loss or be ineffective. The objective of t...
Autores principales: | Barton, Elisabeth R., Pham, Jennifer, Brisson, Becky K., Park, SooHyun, Smith, Lucas R., Liu, Min, Tian, Zuozhen, Hammers, David W., Vassilakos, Georgios, Sweeney, H. Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771521/ https://www.ncbi.nlm.nih.gov/pubmed/31323135 http://dx.doi.org/10.1002/mus.26641 |
Ejemplares similares
-
Insulin-Like Growth Factor-I E-Peptide Activity Is Dependent on the IGF-I Receptor
por: Brisson, Becky K., et al.
Publicado: (2012) -
Dysferlin-Peptides Reallocate Mutated Dysferlin Thereby Restoring Function
por: Schoewel, Verena, et al.
Publicado: (2012) -
Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin‐deficient and mdx mice
por: White, Zoe, et al.
Publicado: (2021) -
Comparison of Dysferlin Expression in Human Skeletal Muscle with That in Monocytes for the Diagnosis of Dysferlin Myopathy
por: Gallardo, Eduard, et al.
Publicado: (2011) -
Minimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice
por: Yasa, Joe, et al.
Publicado: (2023)